Benson Hill Biosystems Raises $25m Series B, Reveals CRISPR 2.0
by Eva | Mar 28, 2017
Benson Hill Biosystems has identified a more precise and efficient gene-editing tool than CRISPR Cas-9, according to Matt Crisp, CEO.
Source: BREAKING EXCLUSIVE: Benson Hill Biosystems Raises $25m Series B, Reveals CRISPR 2.0 – AgFunderNews
Investments in private offerings are speculative, illiquid and involve a high degree of risk and those investors who cannot afford to lose their entire investment and who cannot hold an investment for an indeterminate period should not invest in such offerings. Past performance is not indicative of future results. Securities are offered through North Capital Private Securities, member FINRA/SIPC. All information provided herein should not be relied upon to make an investment decision and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Prospective investors are recommended to consult with a financial adviser, attorney, accountant, and any other professional that can help you understand and assess the risks associated with an investment opportunity.
